Spotlight Series

Stay updated with insights from Adial’s executives on the latest company news and key developments in addiction research.

Strategic Growth & Innovation: Tony Goodman on Adial’s Vision for Precision Medicine

04/03/2025

Adial’s approach with AD04 integrates a genetic focus, specifically targeting certain genotypes. How has this personalized medicine approach been received within the addiction treatment community?

From Data to Recovery: Transforming AUD Treatment with Precision Medicine

01/29/2025

Adial Pharmaceuticals is leveraging genetic insights to redefine AUD care with targeted, patient-specific solutions Since its inception, Adial Pharmaceuticals has recognized the potential of precision medicine in treating Alcohol Use Disorder (AUD). Built on a commitment to scientific innovation, Adial has dedicated itself to developing therapeutic interventions that take into…

news

March 4
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
Continue Reading
February 25
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
Continue Reading
February 19
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
Continue Reading
February 12
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
Continue Reading
January 29
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Continue Reading

Tweets by AdialPharma